A detailed history of Loomis Sayles & CO L P transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, Loomis Sayles & CO L P holds 561,479 shares of RARE stock, worth $15.4 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
561,479
Holding current value
$15.4 Million
% of portfolio
0.03%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025

BUY
$36.21 - $45.78 $20.3 Million - $25.7 Million
561,479 New
561,479 $20.3 Million
Q3 2023

Nov 09, 2023

BUY
$34.92 - $46.66 $2,339 - $3,126
67 Added 78.82%
152 $5,000
Q2 2023

Aug 11, 2023

BUY
$37.35 - $52.15 $3,174 - $4,432
85 New
85 $4,000
Q4 2019

Feb 14, 2020

SELL
$36.08 - $45.83 $8.59 Million - $10.9 Million
-238,194 Closed
0 $0
Q3 2019

Nov 13, 2019

BUY
$42.5 - $63.11 $804,950 - $1.2 Million
18,940 Added 8.64%
238,194 $10.2 Million
Q2 2019

Aug 14, 2019

BUY
$54.93 - $74.36 $12 Million - $16.3 Million
219,254 New
219,254 $13.9 Million

Others Institutions Holding RARE

About Ultragenyx Pharmaceutical Inc.


  • Ticker RARE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 70,036,896
  • Market Cap $1.91B
  • Description
  • Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...
More about RARE
Track This Portfolio

Track Loomis Sayles & CO L P Portfolio

Follow Loomis Sayles & CO L P and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Loomis Sayles & CO L P, based on Form 13F filings with the SEC.

News

Stay updated on Loomis Sayles & CO L P with notifications on news.